2-azabicyclo<3.3.1>non-6-ene | 91652-94-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-azabicyclo<3.3.1>non-6-ene
• 英文别名: 2-Azabicyclo[3.3.1]non-6-ene
• CAS: 91652-94-7
• 化学式: C₈H₁₃N
• mdl: MFCD19220209
• 分子量: 123.198
• InChiKey: JIWONAKAPSMZSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-azabicyclo<3.3.1>non-6-ene 生成 2-phenylsulfonyl-3',6'-bis(methoxycarbonyl)-6,7-(4',5'-pyridazino)-2-azabicyclo<3.3.1>non-6-ene
  参考文献：
  名称：

  Inoue, Hiroo; Origuchi, Toshiki; Umano, Katsumi, Heterocycles, 1984, vol. 21, # 2, p. 656

  摘要：

  DOI：
• 作为产物：
  描述：

  (1R,5S,8S)-2-Benzenesulfonyl-7,8-dichloro-2-aza-bicyclo[3.3.1]non-6-ene 在 lithium aluminium tetrahydride 、 氨 、 sodium 、 lithium chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 2-azabicyclo<3.3.1>non-6-ene
  参考文献：
  名称：

  Inoue, Hiroo; Origuchi, Toshiki; Umano, Katsumi, Heterocycles, 1984, vol. 21, # 2, p. 656

  摘要：

  DOI：

文献信息

• Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
  申请人：Peters Stefan

  公开号：US20110269791A1

  公开（公告）日：2011-11-03

  The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式（I）定义的化合物，其中A、B、X、m、n和o基团的定义如权利要求1中所述，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• A Synthetic Route to the Morphan Ring System by Skeletal Transformation of Norbornadiene
  作者：Hiroo Inoue、Toshiki Origuchi、Katsumi Umano

  DOI：10.1246/bcsj.57.806

  日期：1984.3

  The morphan skeleton was prepared from 2-phenylsulfonyl-2-azabicyclo[3.2.1]oct-6-ene (2), derived from norbornadiene, through the addition of dichlorocarbene to the monoene 2 and the subsequent thermal isomerization of the adduct obtained. The isomerization products, 2-phenylsulfonyl-6,7-dichloro-2-azabicyclo[3.3.1]non-7-ene and 2-phenylsulfonyl-7,8-dichloro-2-azabicyclo[3.3.1]non-6-ene, which are

  吗喃骨架是由 2-苯基磺酰基-2-氮杂双环 [3.2.1] oct-6-烯 (2) 制备的，该物质源自降冰片二烯，通过将二氯卡宾加成到单烯 2 中并随后对所得加合物进行热异构化。异构化产物2-苯基磺酰基-6,7-二氯-2-氮杂双环[3.3.1]non-7-ene和2-苯基磺酰基-7,8-二氯-2-氮杂双环[3.3.1]non-6-烯在氯化锂存在下可相互转化，通过还原脱氯和烷基化作用转化为各种吗喃。此外，通过 1,2,4,5-四嗪-3,6-二甲酸二甲酯与 2-苯基磺酰基-2-氮杂双环[3.3.1]non-6-的环加成反应合成了 6,7-哒嗪基-退火吗喃。烯。
• Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
  申请人：Himmelsbach Frank

  公开号：US20110190262A1

  公开（公告）日：2011-08-04

  The present invention relates to compounds defined by formula I wherein the groups R 1 to R 3 , X, m, n and o are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及公式I所定义的化合物，其中R1至R3、X、m、n和o的定义如权利要求书中所述，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
  申请人：Eckhardt Matthias

  公开号：US20110028445A1

  公开（公告）日：2011-02-03

  The present invention relates to compounds defined by formula (I) wherein the groups A, B, X, m, n and o are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式(I)定义的化合物，其中A，B，X，m，n和o的基团如权利要求1中所定义，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受到影响的疾病，如代谢性疾病，特别是2型糖尿病，肥胖症和血脂异常。
• ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2220048A2

  公开（公告）日：2010-08-25